Synthesis, characterization and biological evaluation of 7 alpha-perfluoroalkylestradiol derivatives. 2003

Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
SIRCOB, ESA CNRS 8086, Université de Versailles, 45 Avenue des Etats-Unis, 78035 Versailles, France. jcblaz@chimie.uvsq.fr

Linkage of a long CH(2 )side chain ('spacer') onto C-7 alpha of estradiol-17 beta (E(2)) does not abrogate the binding affinity of this hormone for its receptor. Our purpose was to assess whether the linkage of a CF(2 )side chain, which is more bulky and rigid, could also be accommodated by the estrogen receptor (ER). We describe here the synthesis of 7 alpha-perfluorohexylestradiol 7 by perfluoroalkylation of a key silylenolether 2 with FITS-6 (perfluorohexyl-phenyliodoniurn trifluoromethanesulfonate). 7 alpha-Trifluoromethylestradiol 10a was prepared as a fluorinated control compound by UV-light induced trifluoromethylation of 2 with Umemoto reagent (S-trifluoromethyldibenzo[b,d]thiophenium trifluoromethanesulfonate). Endocrine properties of these two E(2 )derivatives were tested on the MCF-7 breast cancer cell line. Our data reveal that rigidity of the side chain of 7 affected the association of its hormone moiety with the ER to the same extent as a long alkyl side chain. Rigidity also failed to abrogate estrogenicity, as demonstrated by the ability of 7 to enhance ERE-dependent transcription and cell growth. Compound retained the capacity of inducing down regulation of the receptor. Interestingly, no evidence of antiestrogenicity was recorded since this compound behaved like a weak estrogen, exerting a mitogenic effect at high concentration. Of note, control 10a displayed a higher binding affinity than 7 for ER and consequently acted like the latter, albeit with a higher efficiency. Selection of appropriate residues to be linked at the end of a long 7 alpha alkyl side chain is known to be essential for generating strong antiestrogenicity. One may hope that such a property may also hold for perfluorinated chains to produce antiestrogens with strong metabolic stability.

UI MeSH Term Description Entries
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006845 Hydrocarbons, Fluorinated Inert liquid or gaseous halocarbon compounds in which FLUORINE replaces some or all HYDROGEN atoms. Fluorinated Hydrocarbons
D000478 Alkylation The covalent bonding of an alkyl group to an organic compound. It can occur by a simple addition reaction or by substitution of another functional group. Alkylations
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
March 2010, Archiv der Pharmazie,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
January 2012, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
July 1989, The Journal of antibiotics,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
August 2009, Yao xue xue bao = Acta pharmaceutica Sinica,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
April 2020, Journal of biomolecular structure & dynamics,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
June 2016, European journal of medicinal chemistry,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
April 2007, Bioorganic & medicinal chemistry letters,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
January 2012, Bioorganic & medicinal chemistry letters,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
March 2016, Pakistan journal of pharmaceutical sciences,
Jean-Claude Blazejewski, and Martin P Wilmshurst, and Matthew D Popkin, and Claude Wakselman, and Guy Laurent, and Denis Nonclercq, and Anny Cleeren, and Yan Ma, and Hye-Sook Seo, and Guy Leclercq
April 2015, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!